Semaglutide and tirzepatide achieve approximately 15-20% body weight reduction in clinical trials
Mitochondrial H 2 O 2 signaling is controlled by the concerted action of peroxiredoxin III and sulfiredoxin: Linking mitochondrial function to circadian rhythm
Patients with a history of severe gastrointestinal disease, particularly those with inflammatory bowel disease, severe gastroesophageal reflux disease, or history of pancreatitis, require careful evaluation before considering this therapy
Tell your healthcare provider if you have any new or worse symptoms of heart failure, including shortness of breath, swelling of your ankles or feet, sudden weight gain
Eng J, Kleinman WA, Singh L, Singh G, and Raufman JP